Advertisement

Natural Killer Cell Immunosenescence and Cancer in the Elderly

  • Beatriz Sánchez-Correa
  • Carmen Campos
  • Alejandra Pera
  • Soledad Sánchez Mateos
  • Sara Morgado
  • Raquel TarazonaEmail author
  • Rafael Solana
Chapter

Abstract

Ageing is associated with changes in the immune system that may affect both innate and adaptive immune responses. Well-preserved natural killer (NK) cell cytotoxicity has been considered as a biomarker of healthy ageing and longevity, whereas low NK cytotoxicity is a predictor of morbidity and mortality due to infections. Remodeling of the NK cell compartment occurs in the elderly, probably reflecting the reduction in the output of the immature CD56bright cells and an accumulation of highly differentiated CD56dim CD57+ NK cells. NK cells in the elderly show phenotypic and functional changes as diminished expression of several activating NK cell receptors or decreased proliferative response to cytokines. Age-associated immune deterioration has been recently considered an additional cause for the high incidence of cancer in the elderly since the immune response against tumors goes down with age. Thus, age-associated alterations in NK cell function may constitute a new biomarker associated to the increased incidence of cancer in the elderly.

Keywords

Natural Killer Natural Killer Cell Acute Myeloid Leukemia Major Histocompatibility Complex Class Natural Killer Cell Cytotoxicity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

We apologize to our colleagues whose work was not cited due to space limitations. This work was supported by grants PS09/00723 (to R.S.) from Spanish Ministry of Health and SAF2009-09711 from the Ministry of Science and Innovation of Spain and PRI09A029 (to RT) and grants to INPATT research group from Junta de Extremadura (GRU10104) and from University of Extremadura, cofinanced by European Regional Development Fund (FEDER).

References

  1. Ademmer K, Ebert M, Muller-Ostermeyer F et al (1998) Effector T lymphocyte subsets in human pancreatic cancer: detection of CD8 + CD18+ cells and CD8 + CD103+ cells by multi-epitope imaging. Clin Exp Immunol 112:21–26PubMedGoogle Scholar
  2. Agostara B, Carruba G, Usset A (2008) The management of cancer in the elderly: targeted therapies in oncology. Immun Ageing 5:16PubMedGoogle Scholar
  3. Almeida-Oliveira A, Smith-Carvalho M, Porto LC et al (2011) Age-related changes in natural killer cell receptors from childhood through old age. Hum Immunol 72:319–329PubMedGoogle Scholar
  4. Anisimov VN (2003) The relationship between aging and carcinogenesis: a critical appraisal. Crit Rev Oncol Hematol 45:277–304PubMedGoogle Scholar
  5. Appay V, Sauce D, Prelog M (2010) The role of the thymus in immunosenescence: lessons from the study of thymectomized individuals. Aging (Albany NY) 2:78–81Google Scholar
  6. Bellora F, Castriconi R, Dondero A et al (2010) The interaction of human natural killer cells with either unpolarized or polarized macrophages results in different functional outcomes. Proc Natl Acad Sci U S A 107:21659–21664PubMedGoogle Scholar
  7. Bernal M, Ruiz-Cabello F, Concha A et al (2012) Implication of the beta2-microglobulin gene in the generation of tumor escape phenotypes. Cancer Immunol Immunother 61:1359–1371PubMedGoogle Scholar
  8. Bjorkstrom NK, Riese P, Heuts F et al (2010) Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK cell differentiation uncoupled from NK cell education. Blood 116:3853–3864PubMedGoogle Scholar
  9. Borrego F, Alonso MC, Galiani MD et al (1999) NK phenotypic markers and IL2 response in NK cells from elderly people. Exp Gerontol 34:253–265PubMedGoogle Scholar
  10. Bruunsgaard H, Pedersen AN, Schroll M et al (2001) Decreased natural killer cell activity is associated with atherosclerosis in elderly humans. Exp Gerontol 37:127–136PubMedGoogle Scholar
  11. Bryceson YT, Chiang SC, Darmanin S et al (2011) Molecular mechanisms of natural killer cell activation. J Innate Immun 3:216–226PubMedGoogle Scholar
  12. Camous X, Pera A, Solana R et al (2012) NK cells in healthy aging and age-associated diseases. J Biomed Biotechnol 195956Google Scholar
  13. Carlsten M, Norell H, Bryceson YT et al (2009) Primary human tumor cells expressing CD155 impair tumor targeting by down-regulating DNAM-1 on NK cells. J Immunol 183:4921–4930PubMedGoogle Scholar
  14. Carrega P, Morandi B, Costa R et al (2008) Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56 bright CD16(−) cells and display an impaired capability to kill tumor cells. Cancer 112:863–875PubMedGoogle Scholar
  15. Casado JG, Pawelec G, Morgado S et al (2009) Expression of adhesion molecules and ligands for activating and costimulatory receptors involved in cell-mediated cytotoxicity in a large panel of human melanoma cell lines. Cancer Immunol Immunother 58:1517–1526PubMedGoogle Scholar
  16. Chan CJ, Andrews DM, Smyth MJ (2012) Receptors that interact with nectin and nectin-like proteins in the immunosurveillance and immunotherapy of cancer. Curr Opin Immunol 24:246–251PubMedGoogle Scholar
  17. Chidrawar SM, Khan N, Chan YL et al (2006) Ageing is associated with a decline in peripheral blood CD56bright NK cells. Immun Ageing 3:10PubMedGoogle Scholar
  18. De MM, Franceschi C, Monti D et al (2005) Inflamm-ageing and lifelong antigenic load as major determinants of ageing rate and longevity. FEBS Lett 579:2035–2039Google Scholar
  19. DelaRosa O, Pawelec G, Peralbo E et al (2006) Immunological biomarkers of ageing in man: changes in both innate and adaptive immunity are associated with health and longevity. Biogerontology 7:471–481PubMedGoogle Scholar
  20. Derhovanessian E, Solana R, Larbi A et al (2008) Immunity, ageing and cancer. Immun Ageing 5:11PubMedGoogle Scholar
  21. Falandry C, Gilson E, Rudolph KL (2013) Are aging biomarkers clinically relevant in oncogeriatrics? Crit Rev Oncol Hematol 85:257–265PubMedGoogle Scholar
  22. Farnault L, Sanchez C, Baier C et al (2012) Hematological malignancies escape from NK cell innate immune surveillance: mechanisms and therapeutic implications. Clin Dev Immunol 2012:421702PubMedGoogle Scholar
  23. Fauriat C, Just-Landi S, Mallet F et al (2007) Deficient expression of NCR in NK cells from acute myeloid leukemia: evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction. Blood 109:323–330PubMedGoogle Scholar
  24. Ferlay J, Shin HR, Bray F et al (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893–2917PubMedGoogle Scholar
  25. Fernandez-Messina L, Reyburn HT, Vales-Gomez M (2012) Human NKG2D-ligands: cell biology strategies to ensure immune recognition. Front Immunol 3:299PubMedGoogle Scholar
  26. Ferrando-Martinez S, Ruiz-Mateos E, Hernandez A et al (2011) Age-related deregulation of naive T cell homeostasis in elderly humans. Age (Dordr) 33:197–207Google Scholar
  27. Franceschi C, Bonafe M, Valensin S et al (2000) Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci 908:244–254PubMedGoogle Scholar
  28. Freud AG, Caligiuri MA (2006) Human natural killer cell development. Immunol Rev 214:56–72PubMedGoogle Scholar
  29. Fuchs A, Colonna M (2006) The role of NK cell recognition of nectin and nectin-like proteins in tumor immunosurveillance. Semin Cancer Biol 16:359–366PubMedGoogle Scholar
  30. Fulop T, Kotb R, Fortin CF et al (2010a) Potential role of immunosenescence in cancer development. Ann N Y Acad Sci 1197:158–165PubMedGoogle Scholar
  31. Fulop T, Larbi A, Witkowski JM et al (2010b) Aging, frailty and age-related diseases. Biogerontology 11:547–563PubMedGoogle Scholar
  32. Garrido F, Cabrera T, Aptsiauri N (2010) “Hard” and “soft” lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapy. Int J Cancer 127:249–256PubMedGoogle Scholar
  33. Gayoso I, Peralbo E, Sanchez-Correa B et al (2009) Phenotypic analysis of human NK cells in healthy elderly. Medimond s.r.l, Bologna, pp 105–109Google Scholar
  34. Gayoso I, Sanchez-Correa B, Campos C et al (2011) Immunosenescence of human natural killer cells. J Innate Immun 3:337–343PubMedGoogle Scholar
  35. Gregg R, Smith CM, Clark FJ et al (2005) The number of human peripheral blood CD4+ CD25high regulatory T cells increases with age. Clin Exp Immunol 140:540–546PubMedGoogle Scholar
  36. Gribben JG (2011) Are prognostic factors in CLL overrated? Oncology (Williston Park) 25:703–706Google Scholar
  37. Halama N, Braun M, Kahlert C et al (2011) Natural killer cells are scarce in colorectal carcinoma tissue despite high levels of chemokines and cytokines. Clin Cancer Res 17:678–689PubMedGoogle Scholar
  38. Hayhoe RP, Henson SM, Akbar AN et al (2010) Variation of human natural killer cell phenotypes with age: identification of a unique KLRG1-negative subset. Hum Immunol 71:676–681PubMedGoogle Scholar
  39. Hilpert J, Grosse-Hovest L, Grunebach F et al (2012) Comprehensive analysis of NKG2D ligand expression and release in leukemia: implications for NKG2D-mediated NK cell responses. J Immunol 189:1360–1371PubMedGoogle Scholar
  40. Hirokawa K, Utsuyama M, Ishikawa T et al (2009) Decline of T cell-related immune functions in cancer patients and an attempt to restore them through infusion of activated autologous T cells. Mech Ageing Dev 130:86–91PubMedGoogle Scholar
  41. Holtan SG, Creedon DJ, Thompson MA et al (2011) Expansion of CD16-negative natural killer cells in the peripheral blood of patients with metastatic melanoma. Clin Dev Immunol 2011:316314PubMedGoogle Scholar
  42. Ishigami S, Natsugoe S, Tokuda K et al (2000a) Clinical impact of intratumoral natural killer cell and dendritic cell infiltration in gastric cancer. Cancer Lett 159:103–108PubMedGoogle Scholar
  43. Ishigami S, Natsugoe S, Tokuda K et al (2000b) Prognostic value of intratumoral natural killer cells in gastric carcinoma. Cancer 88(3):577–583PubMedGoogle Scholar
  44. Jabbour EJ, Estey E, Kantarjian HM (2006) Adult acute myeloid leukemia. Mayo Clin Proc 81:247–260PubMedGoogle Scholar
  45. Koch S, Solana R, Dela RO et al (2006) Human cytomegalovirus infection and T cell immunosenescence: a mini review. Mech Ageing Dev 127:538–543PubMedGoogle Scholar
  46. Konjevic G, Mirjacic MK, Jurisic V et al (2009) Biomarkers of suppressed natural killer (NK) cell function in metastatic melanoma: decreased NKG2D and increased CD158a receptors on CD3-CD16+ NK cells. Biomarkers 14:258–270PubMedGoogle Scholar
  47. Krieg S, Ullrich E (2013) Novel immune modulators used in hematology: impact on NK cells. Front Immunol 3:388PubMedGoogle Scholar
  48. Kutza J, Murasko DM (1994) Effects of aging on natural killer cell activity and activation by interleukin-2 and IFN-alpha. Cell Immunol 155:195–204PubMedGoogle Scholar
  49. Kutza J, Murasko DM (1996) Age-associated decline in IL-2 and IL-12 induction of LAK cell activity of human PBMC samples. Mech Ageing Dev 90:209–222PubMedGoogle Scholar
  50. Larbi A, Franceschi C, Mazzatti D et al (2008) Aging of the immune system as a prognostic factor for human longevity. Physiology (Bethesda) 23:64–74Google Scholar
  51. Le Garff-Tavernier M, Beziat V, Decocq J et al (2010) Human NK cells display major phenotypic and functional changes over the life span. Aging Cell 9:527–535PubMedGoogle Scholar
  52. Lee SK, Gasser S (2010) The role of natural killer cells in cancer therapy. Front Biosci (Elite Ed) 2:380–391Google Scholar
  53. Levy EM, Roberti MP, Mordoh J (2011) Natural killer cells in human cancer: from biological functions to clinical applications. J Biomed Biotechnol 2011:676198PubMedGoogle Scholar
  54. Lopez-Verges S, Milush JM, Pandey S et al (2010) CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK cell subset. Blood 116:3865–3874PubMedGoogle Scholar
  55. Lustgarten J (2009) Cancer, aging and immunotherapy: lessons learned from animal models. Cancer Immunol Immunother 58:1979–1989PubMedGoogle Scholar
  56. Lutz CT, Moore MB, Bradley S et al (2005) Reciprocal age related change in natural killer cell receptors for MHC class I. Mech Ageing Dev 126:722–731PubMedGoogle Scholar
  57. Malaguarnera L, Cristaldi E, Malaguarnera M (2010) The role of immunity in elderly cancer. Crit Rev Oncol Hematol 74:40–60PubMedGoogle Scholar
  58. Mariani E, Monaco MC, Cattini L et al (1994) Distribution and lytic activity of NK cell subsets in the elderly. Mech Ageing Dev 76:177–187PubMedGoogle Scholar
  59. Mariani E, Meneghetti A, Neri S et al (2002) Chemokine production by natural killer cells from nonagenarians. Eur J Immunol 32:1524–1529PubMedGoogle Scholar
  60. Mariani E, Meneghetti A, Formentini I et al (2003a) Telomere length and telomerase activity: effect of ageing on human NK cells. Mech Ageing Dev 124:403–408PubMedGoogle Scholar
  61. Mariani E, Meneghetti A, Formentini I et al (2003b) Different rates of telomere shortening and telomerase activity reduction in CD8 T and CD16 NK lymphocytes with ageing. Exp Gerontol 38:653–659PubMedGoogle Scholar
  62. Markel G, Seidman R, Besser MJ et al (2009) Natural killer lysis receptor (NKLR)/NKLR-ligand matching as a novel approach for enhancing anti-tumor activity of allogeneic NK cells. PLoS One 4:e5597PubMedGoogle Scholar
  63. Mazzola P, Radhi S, Mirandola L et al (2012) Aging, cancer, and cancer vaccines. Immun Ageing 9:4–9PubMedGoogle Scholar
  64. Mendez R, Aptsiauri N, Del CA et al (2009) HLA and melanoma: multiple alterations in HLA class I and II expression in human melanoma cell lines from ESTDAB cell bank. Cancer Immunol Immunother 58:1507–1515PubMedGoogle Scholar
  65. Morgado S, Sanchez-Correa B, Casado JG et al (2011) NK cell recognition and killing of melanoma cells is controlled by multiple activating receptor-ligand interactions. J Innate Immun 3:365–373PubMedGoogle Scholar
  66. Morisaki T, Onishi H, Katano M (2012) Cancer immunotherapy using NKG2D and DNAM-1 systems. Anticancer Res 32:2241–2247PubMedGoogle Scholar
  67. Murasko DM, Jiang J (2005) Response of aged mice to primary virus infections. Immunol Rev 205:285–296PubMedGoogle Scholar
  68. Myers CE, Mirza NN, Lustgarten J (2011) Immunity, cancer and aging: lessons from mouse models. Ageing Dis 2:512–523Google Scholar
  69. Nüssler NC, Stange BJ, Petzold M et al (2007) Reduced NK-cell activity in patients with metastatic colon cancer. Exp Clin Sci 6:1–9Google Scholar
  70. Ogata K, An E, Shioi Y et al (2001) Association between natural killer cell activity and infection in immunologically normal elderly people. Clin Exp Immunol 124:392–397PubMedGoogle Scholar
  71. Panda A, Arjona A, Sapey E et al (2009) Human innate immunosenescence: causes and consequences for immunity in old age. Trends Immunol 30:325–333PubMedGoogle Scholar
  72. Papanikolaou IS, Lazaris AC, Apostolopoulos P et al (2004) Tissue detection of natural killer cells in colorectal adenocarcinoma. BMC Gastroenterol 4:20PubMedGoogle Scholar
  73. Paschen A, Sucker A, Hill B et al (2009) Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B. Clin Cancer Res 15:5208–5215PubMedGoogle Scholar
  74. Pavlidis N, Stanta G, Audisio RA (2012) Cancer prevalence and mortality in centenarians: a systematic review. Crit Rev Oncol Hematol 83:145–152PubMedGoogle Scholar
  75. Pawelec G, Solana R (1997) Immunosenescence. Immunol Today 18:514–516PubMedGoogle Scholar
  76. Pawelec G, Solana R (2008) Are cancer and ageing different sides of the same coin? Conference on Cancer and Ageing. EMBO Rep 9:234–238PubMedGoogle Scholar
  77. Pawelec G, Adibzadeh M, Solana R et al (1997) The T cell in the ageing individual. Mech Ageing Dev 93:35–45PubMedGoogle Scholar
  78. Pawelec G, Remarque E, Barnett Y et al (1998a) T cells and aging. Front Biosci 3:d59–d99PubMedGoogle Scholar
  79. Pawelec G, Solana R, Remarque E et al (1998b) Impact of aging on innate immunity. J Leukoc Biol 64:703–712PubMedGoogle Scholar
  80. Pawelec G, Barnett Y, Forsey R et al (2002) T cells and aging, January 2002 update. Front Biosci 7:d1056–d1183PubMedGoogle Scholar
  81. Pawelec G, Derhovanessian E, Larbi A (2010) Immunosenescence and cancer. Crit Rev Oncol Hematol 75:165–172PubMedGoogle Scholar
  82. Pegram HJ, Andrews DM, Smyth MJ et al (2011) Activating and inhibitory receptors of natural killer cells. Immunol Cell Biol 89:216–224PubMedGoogle Scholar
  83. Pende D, Bottino C, Castriconi R et al (2005) PVR (CD155) and Nectin-2 (CD112) as ligands of the human DNAM-1 (CD226) activating receptor: involvement in tumor cell lysis. Mol Immunol 42:463–469PubMedGoogle Scholar
  84. Platonova S, Cherfils-Vicini J, Damotte D et al (2011) Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. Cancer Res 71:5412–5422PubMedGoogle Scholar
  85. Porrata LF, Inwards DJ, Ansell SM et al (2008) Early lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin lymphoma: a prospective study. Biol Blood Marrow Transplant 14:807–816PubMedGoogle Scholar
  86. Raulet DH, Gasser S, Gowen BG et al (2013) Regulation of ligands for the NKG2D activating receptor. Annu Rev Immunol 31:413–441PubMedGoogle Scholar
  87. Remarque E, Pawelec G (1998) T cell immunosenescence and its clinical relevance in man. Rev Clin Gerontol 8:5–14Google Scholar
  88. Salih HR, Holdenrieder S, Steinle A (2008) Soluble NKG2D ligands: prevalence, release, and functional impact. Front Biosci 13:3448–3456PubMedGoogle Scholar
  89. Sanchez-Correa B, Morgado S, Gayoso I et al (2011) Human NK cells in acute myeloid leukaemia patients: analysis of NK cell-activating receptors and their ligands. Cancer Immunol Immunother 60:1195–1205PubMedGoogle Scholar
  90. Sanchez-Correa B, Gayoso I, Bergua JM et al (2012) Decreased expression of DNAM-1 on NK cells from acute myeloid leukemia patients. Immunol Cell Biol 90:109–115PubMedGoogle Scholar
  91. Sanchez-Correa B, Bergua JM, Campos C et al (2013) Cytokine profiles in acute myeloid leukemia patients at diagnosis: survival is inversely correlated with IL-6 and directly correlated with IL-10 levels. Cytokine 61(3):885–891PubMedGoogle Scholar
  92. Schnurr M, Scholz C, Rothenfusser S et al (2002) Apoptotic pancreatic tumor cells are superior to cell lysates in promoting cross-priming of cytotoxic T cells and activate NK and gammadelta T cells. Cancer Res 62:2347–2352PubMedGoogle Scholar
  93. Schreiber RD, Old LJ, Smyth MJ (2011) Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 331:1565–1570PubMedGoogle Scholar
  94. Schwinn N, Vokhminova D, Sucker A et al (2009) Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells. Int J Cancer 124:1594–1604PubMedGoogle Scholar
  95. Siegrist CA, Aspinall R (2009) B-cell responses to vaccination at the extremes of age. Nat Rev Immunol 9:185–194PubMedGoogle Scholar
  96. Solana R, Mariani E (2000) NK and NK/T cells in human senescence. Vaccine 18:1613–1620PubMedGoogle Scholar
  97. Solana R, Pawelec G, Tarazona R (2006) Aging and innate immunity. Immunity 24:491–494PubMedGoogle Scholar
  98. Solana R, Casado JG, Delgado E et al (2007) Lymphocyte activation in response to melanoma: interaction of NK-associated receptors and their ligands. Cancer Immunol Immunother 56:101–109PubMedGoogle Scholar
  99. Solana R, Tarazona R, Gayoso I et al (2012) Innate immunosenescence: effect of aging on cells and receptors of the innate immune system in humans. Semin Immunol 24:331–341PubMedGoogle Scholar
  100. Stojanovic A, Cerwenka A (2011) Natural killer cells and solid tumors. J Innate Immun 3:355–364PubMedGoogle Scholar
  101. Takeuchi H, Maehara Y, Tokunaga E et al (2001) Prognostic significance of natural killer cell activity in patients with gastric carcinoma: a multivariate analysis. Am J Gastroenterol 96:574–578PubMedGoogle Scholar
  102. Tarazona R, DelaRosa O, Alonso C et al (2000) Increased expression of NK cell markers on T lymphocytes in aging and chronic activation of the immune system reflects the accumulation of effector/senescent T cells. Mech Ageing Dev 121:77–88PubMedGoogle Scholar
  103. Tarazona R, Casado JG, DelaRosa O et al (2002) Selective depletion of CD56(dim) NK cell subsets and maintenance of CD56(bright) NK cells in treatment-naive HIV-1-seropositive individuals. J Clin Immunol 22:176–183PubMedGoogle Scholar
  104. Tarazona R, Gayoso I, Alonso C et al (2009) NK cells in human ageing. In: Fulop T, Franceschi C, Hirokawa K, Pawelec G (eds) Handbook on Immunosenescence. Springer, New York, pp 533–546Google Scholar
  105. Thielens A, Vivier E, Romagne F (2012) NK cell MHC class I specific receptors (KIR): from biology to clinical intervention. Curr Opin Immunol 24:239–245PubMedGoogle Scholar
  106. Vasto S, Candore G, Balistreri CR et al (2007) Inflammatory networks in ageing, age-related diseases and longevity. Mech Ageing Dev 128:83–91PubMedGoogle Scholar
  107. Verheyden S, Demanet C (2008) NK cell receptors and their ligands in leukemia. Leukemia 22:249–257PubMedGoogle Scholar
  108. Vesely MD, Kershaw MH, Schreiber RD et al (2011) Natural innate and adaptive immunity to cancer. Annu Rev Immunol 29:235–271PubMedGoogle Scholar
  109. Vivier E, Tomasello E, Baratin M et al (2008) Functions of natural killer cells. Nat Immunol 9:503–510PubMedGoogle Scholar
  110. Vivier E, Raulet DH, Moretta A et al (2011) Innate or adaptive immunity? The example of natural killer cells. Science 331:44–49PubMedGoogle Scholar
  111. Wagner WM, Ouyang Q, Sekeri-Pataryas K et al (2004) Basic biology and clinical impact of immunosenescence. Biogerontology 5:63–66PubMedGoogle Scholar
  112. Wehner R, Dietze K, Bachmann M et al (2011) The bidirectional crosstalk between human dendritic cells and natural killer cells. J Innate Immun 3:258–263PubMedGoogle Scholar
  113. Whiteside TL (2013) Immune modulation of T-cell and NK (natural killer) cell activities by TEXs (tumour-derived exosomes). Biochem Soc Trans 41:245–251PubMedGoogle Scholar
  114. Wikby A, Nilsson BO, Forsey R et al (2006) The immune risk phenotype is associated with IL-6 in the terminal decline stage: findings from the Swedish NONA immune longitudinal study of very late life functioning. Mech Ageing Dev 127:695–704PubMedGoogle Scholar
  115. Yang C, Robbins PD (2011) The roles of tumor-derived exosomes in cancer pathogenesis. Clin Dev Immunol 2011:842849PubMedGoogle Scholar
  116. Zamai L, Ponti C, Mirandola P et al (2007) NK cells and cancer. J Immunol 178:4011–4016PubMedGoogle Scholar
  117. Zhang Y, Wallace DL, de Lara CM et al (2007) In vivo kinetics of human natural killer cells: the effects of ageing and acute and chronic viral infection. Immunology 121:258–265PubMedGoogle Scholar
  118. Zhou Z, Zhang C, Zhang J et al (2012) Macrophages help NK cells to attack tumor cells by stimulatory NKG2D ligand but protect themselves from NK killing by inhibitory ligand Qa-1. PLoS One 7:e36928PubMedGoogle Scholar
  119. Zimmer J, Andres E, Hentges F (2008) NK cells and Treg cells: a fascinating dance cheek to cheek. Eur J Immunol 38:2942–2945PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Beatriz Sánchez-Correa
    • 1
  • Carmen Campos
    • 2
  • Alejandra Pera
    • 2
  • Soledad Sánchez Mateos
    • 1
  • Sara Morgado
    • 1
  • Raquel Tarazona
    • 1
    Email author
  • Rafael Solana
    • 2
  1. 1.Immunology Unit, Department of PhysiologyUniversity of ExtremaduraCáceresSpain
  2. 2.Department of ImmunologyIMIBIC – Reina Sofia University Hospital – University of CordobaCordobaSpain

Personalised recommendations